Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition.

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Malnutrition, Sarcopenia

In brief

Aging is associated with an increased inflammation named "inflammageing" and with an altered immune response. Different mechanisms have been proposed to explain the phenomenon of inflammageing and increased oxidative stress: deficiencies in essential amino acids, and some micronutrients have an important impact and may induce immune cell dysregulation. Mitochondrial dysfunction may explain the complex relationship between malnutrition sarcopenia, immune dysfunction and aging. Therefore, a personalized nutritional strategy aiming to improve mitochondrial function, decrease oxidative stress, down-regulate inflammation and restore immunity appears to be a logical approach in order to treat malnutrition and its biological and clinical consequences. MIMOSA will investigate the role of nutritional supplements in rescuing altered mitochondrial function and redox state imbalance.

Key facts

Study ID

NCT05324475

Run by

Patrizia D'Amelio

People needed

240

Starts

2025-04-01

Expected to finish

2028-03-30

Last updated by the study team

2025-05-31

Who can join

Age: 75 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥75 years
• Patients entering a rehabilitation program
• Diagnosis of malnutrition defined by a MNA-SF (mini-nutritional assessment short form) score below 11 points.
• Commitment to accept the nutritional supplement proposed, willing and able to give written informed consent
• Ability to understand and comply with the requirements of the study

You may not qualify if…

• Presence of malignancy,
• Life expectancy of less than two months calculated by Multidimensional Prognostic Index (MPI ),
• Congestive heart failure (NYHA IV),
• Chronic renal disease (creatinine clearance <40 ml/min calculated by cockroft),
• Liver cirrhosis (Child B-C),
• Tube/percutaneous endoscopic gastrostomy feeding or parenteral nutrition,
• Severe dysphagia,
• Mini-Mental State Examination (MMSE)≤18 and MNA>11 points. MMSE ≥ 18 identifies patients with mild form of cognitive impairment; those patients generally do not have problems in swallowing and are able to take drugs.
• Severe anaemia (Hb<10 g/l) or leukopenia (<2G/l).

Where it is running

• CHUV — Lausanne, Switzerland, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.